Posttranslational modification of therapeutic proteins in plants.
Plants have emerged as an alternative to current systems for the production of therapeutic proteins. The advantages of plants for the low-cost and large-scale production of safe and biologically active mammalian proteins have been documented recently. A major advantage of transgenic plants over production systems that are based on yeast or Escherichia coli is their ability to perform most of the posttranslational modifications (PTMs) that are required for the bioactivity and pharmacokinetics of recombinant therapeutic proteins. Furthermore, recent advances in the control of PTMs in transgenic plants have made it possible for plants to perform, at least to some extent, human-like modifications of recombinant proteins. Hence, plants have become a suitable alternative to animal cell factories for the production of therapeutic proteins.
CNRS UMR 6037-IFRMP 23-GDR 2590, Université de Rouen-Bâtiment de Biologie (extension), Blvd de Broglie, 76821 Mont Saint Aignan Cedex, France. vgomord@crihan.fr
Véronique
V
Gomord
Loïc
L
Faye
D001685:Biological Factors / Q000096:biosynthesis* / Q000737:chemistry; D005227:Fatty Acids / Q000737:chemistry / Q000378:metabolism; D005818:Genetic Engineering / Q000379:methods; D006031:Glycosylation; D007477:Ions / Q000737:chemistry / Q000378:metabolism; D010084:Oxidation-Reduction; D010940:Plant Proteins / Q000235:genetics* / Q000378:metabolism; D010944:Plants / Q000235:genetics* / Q000378:metabolism; D011499:Protein Processing, Post-Translational / Q000235:genetics*
D001685:Biological Factors; D005227:Fatty Acids; D007477:Ions; D010940:Plant Proteins